Patents Assigned to Eisai Research Institute
  • Publication number: 20070129402
    Abstract: The invention provides sustained release formulations comprising donepezil, stereoisomers of donepezil, pharmaceutically acceptable salts of donepezil, or pharmaceutically acceptable salts of stereoisomers of donepezil. The formulations have desirable pharmacokinetic characteristics. Examples include AUC, Tmax, Cmax, dosage-corrected AUC, and dosage-corrected Cmax.
    Type: Application
    Filed: June 27, 2006
    Publication date: June 7, 2007
    Applicant: Eisai Research Institute
    Inventors: Yosuke Ueki, Satoshi Fujioka, Shigeru Aoki
  • Publication number: 20060280789
    Abstract: The invention provides sustained release formulations of basic drugs, stereoisomers of basic drugs, pharmaceutically acceptable salts of basic drugs, and pharmaceutically acceptable salts of stereoisomers of basic drugs. The basic drugs may be anti-dementia drugs, such as cholinesterase inhibitors or memantine. In one embodiment, the cholinesterase inhibitor is donepezil.
    Type: Application
    Filed: December 27, 2005
    Publication date: December 14, 2006
    Applicant: Eisai Research Institute
    Inventors: Yosuke Ueki, Satoshi Fujioka, Shigeru Aoki, Susan Abu-Shakra, J. Carter, Gary Dorough
  • Patent number: 7125716
    Abstract: Provided are a method of producing a culturable cell with no nucleus, showing mitochondrial activity, comprising: performing cell fusion between a nucleus-less cell having mitochondrial DNA and a mitochondrial DNA-less cultured cell derived from a cancer cell; culturing resulting cybrid cells; and recovering floating cells from obtained cultured cells, and a cell obtained by the method.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: October 24, 2006
    Assignee: Eisai Research Institute
    Inventors: Kazutoshi Nakano, Shigeo Ohta
  • Publication number: 20060194833
    Abstract: The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E6070.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 31, 2006
    Applicant: Eisai Research Institute
    Inventors: Charles Chase, Ikuo Kushida
  • Patent number: 7067714
    Abstract: A non-human animal in which a gene coding for the N-type calcium channel is disrupted to lack functional N-type calcium channel, and a method for screening for a substance having a pharmacological action on blood pressure control, transmission of pain, blood sugar level control and so forth by using the animal.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: June 27, 2006
    Assignee: Eisai Research Institute
    Inventors: Mitsuhiro Ino, Norimasa Miyamoto, Eiki Takahashi, Toru Oki, Takashi Yoshinaga, Shinji Hatakeyama, Tetsuhiro Niidome, Kohei Sawada, Yukio Nishizawa, Isao Tanaka